Try our Advanced Search for more refined results

July 28, 2017

Shanawaz v. Intellipharmaceutics International Inc. et al

Track this case

Case Number:

1:17-cv-05761

Court:

New York Southern

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

J. Paul Oetken

Firms

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. November 12, 2019

    Opioid Co. Inks $1.6M Deal To End Suit Over FDA Rejection

    Canadian drugmaker Intellipharmaceutics International Inc. has agreed to pay investors $1.6 million to settle a proposed class action alleging the company overstated opioid painkiller Rexista's ability to deter abuse before the U.S. Food and Drug Administration rejected its approval.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login